Volatolomics in healthcare and its advanced detection technology

Various diseases increasingly challenge the health status and life quality of human beings.Volatolome emitted from patients has been considered as a potential family of markers,volatolomics,for diagnosis/screening.There are two fundamental issues of volatolomics in healthcare.On one hand,the solid relationship between the volatolome and specific diseases needs to be clarified and verified.On the other hand,effective methods should be explored for the precise detection of volatolome.Several comprehensive review articles had been published in this field.However,a timely and systematical summary and elaboration is still desired.In this review article,the research methodology of volatolomics in healthcare is critically considered and given out,at first.Then,the sets of volatolome according to specific diseases through different body sources and the analytical instruments for their identifications are systematically summarized.Thirdly,the advanced electronic nose and photonic nose technologies for volatile organic compounds(VOCs)detection are well introduced.The existed obstacles and future perspectives are deeply thought and discussed.This article could give a good guidance to researchers in this interdisciplinary field,not only understanding the cutting-edge detection technologies for doctors(medicinal background),but also making reference to clarify the choice of aimed VOCs during the sensor research for chemists,materials scientists,electronics engineers,etc.

The 150 most important questions in cancer research and clinical oncology series:questions 67–75

Since the beginning of 2017, Chinese Journal of Cancer has published a series of important questions in cancer research and clinical oncology, which sparkle diverse thoughts, interesting communications, and potential collaborations among researchers all over the world. In this article, 9 more questions are presented as followed. Question 67. How could we overcome the resistance of hepatocellular carcinoma against chemotherapeutics? Question 68. Is pursuit of non-covalent small-molecule binders of RAS proteins viable as a strategy of cancer drug discovery? Question 69. In what oligomeric structures do RAS proteins signal? Question 70. How can we achieve non-invasive early detection and diagnosis of lung cancer? Question 71. Does genetic information influence the volatolome enabling diagnosis of lung cancer with genetic mutations via cell headspace or breath analysis? Question 72. Is heavy ion beam radiotherapy e ective to kill cancer stem cells? Question 73. Is there any diversity among di erent types of cancer in terms of sensitivity to heavy ion beam radiotherapy? Question 74. Can targeted alpha-particle therapy augment the e ect of carbon ion radiotherapy on malignancies? Question 75. How does chromosomal instability drive tumor progression?